Type2diabetes study: Empagliflozin vs Acipimox
Official title Ketones, SGLT2, HFrEF
ClinicalTrials.gov ID: NCT06229678
What this study is testing
What is Empagliflozin 25 MG Oral Tablet?
an investigational oral tablet being studied as a potential treatment for type 2 diabetes with heart failure and reduced ejection fraction is designed to block the sodium‑glucose co‑transporter‑2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion
Also referred to as Jardiance.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study looks at how a specific diabetes medicine changes the levels of ketones in the blood and how that affects how well the heart muscle pumps and relaxes.
- Who it's for
- The study is looking for adults who have type 2 diabetes and heart failure where the heart does not pump blood as well as it should.
- What's involved
- Participants will start taking a new diabetes medication and undergo tests to measure blood ketone levels and check how their heart is working.
- Time commitment
- The source text does not specify the total duration of the study or the number of visits required.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Type 2 Diabetes Mellitus
- Class II-III New York Heart Association (NYHA) heart failure and reduced ejection fraction (EF) \<50%
- Age 18-80 years
- BMI 23-44 kg/m2
- Glycated hemoglobin (HbA1c) 6.0-10.0%
You likely can't join if
- Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, severe valvular heart disease, hypertrophic...
- Significant change in diuretic management during the month prior to screening (defined by doubling of diuretic dose or addition of another heart...
- Type 2 Diabetics treated with Dipeptidyl Peptidase-4 Inhibitor (DPP4i) or pioglitazone
- Pregnancy, lactation, or plans to become pregnant. A negative pregnancy test will be performed before each MRI study to assess current status.
- Allergy/sensitivity to study drugs or their ingredients.
- Cancer.
See the full eligibility criteria
- Type 2 Diabetes Mellitus
- Class II-III New York Heart Association (NYHA) heart failure and reduced ejection fraction (EF) \<50%
- Age 18-80 years
- BMI 23-44 kg/m2
- Glycated hemoglobin (HbA1c) 6.0-10.0%
- Blood Pressure (BP) ≤ 145/85 mmHg
- Estimated glomerular filtration rate (eGFR) ≥30 ml/min 1.73 m2
- Only Type 2 diabetics treated with diet/exercise, metformin, sulfonylureas, metformin/sulfonylurea, Glucagon-like peptide-1 receptor agonist (GLP-1 RA), or insulin
- Stable body weight (±4 pounds) over the previous 3 months prior to enrollment
- Ability to understand study procedures and to comply with them for the entire length of the study.
- Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, severe valvular heart disease, hypertrophic obstructive cardiomyopathy.
- Significant change in diuretic management during the month prior to screening (defined by doubling of diuretic dose or addition of another heart failure medication)
- Type 2 Diabetics treated with Dipeptidyl Peptidase-4 Inhibitor (DPP4i) or pioglitazone
- Pregnancy, lactation, or plans to become pregnant. A negative pregnancy test will be performed before each MRI study to assess current status.
- Allergy/sensitivity to study drugs or their ingredients.
- Cancer.
- Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
The study team makes the final eligibility decision.
Where it is enrolling
- San Antonio, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Antonio, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.